Skip to Main content Skip to Navigation

Le système circadien : cible pharmacologique pour prévenir ou améliorer les symptômes associés au cancer et à ses traitements

Abstract : The circadian timing system controls several temporal aspects of physiology and behaviour in laboratory animals and humans. The disruption of the circadian timing system results in the occurrence of alterations at various levels of organisation: central coordination, circadian physiology, molecular clocks and signalling pathways. In particular, a circadian disruption induced by long-haul flights across several time-zones or by shift work is associated with the appearance of systemic symptoms, such as fatigue, mood disorders and appetite loss. These symptoms, related to circadian disruption, are also frequently found in cancer patients, as a consequence of their neoplastic disease or its treatment. My PhD work is part of the research regarding the role of the circadian timing system in the development of the symptoms associated with cancer and its treatment, in tumor progression and in patients’ survival. Its perspective is to identify novel therapeutic options. In particular, the general objectives of this thesis consist in the definition of the relationships between symptoms and circadian function of patients before and during chemotherapy, and in the quantification of the clinical impact of circadian disruption on quality of life and survival. I have focused in particular on patients with metastatic colorectal cancer, third cancer for incidence and mortality. These studies confirm the role of the circadian timing system in the occurrence of systemic symptoms in cancer patients, without treatment or during it. This study is currently ongoing in collaboration with the NIH in the United States. In conclusion, this work leads me to propose an innovative therapeutic approach aimed at shielding and/or restoring the integrity of the circadian timing system. This novel strategy should improve the therapeutic index of chemotherapy, by increasing its efficacy and decreasing its toxicity, still reducing the occurrence of symptoms, preserving the quality of life and prolonging the survival of cancer patients. The implementation of this strategy relies on the non-invasive monitoring of biomarkers of the circadian timing system and on the personalization of chronotherapy delivery.
Document type :
Complete list of metadata
Contributor : ABES STAR :  Contact
Submitted on : Wednesday, August 1, 2012 - 1:03:01 AM
Last modification on : Wednesday, October 14, 2020 - 3:41:41 AM
Long-term archiving on: : Friday, November 2, 2012 - 2:25:11 AM


Version validated by the jury (STAR)


  • HAL Id : tel-00722229, version 1



Pasquale Fabio Innominato. Le système circadien : cible pharmacologique pour prévenir ou améliorer les symptômes associés au cancer et à ses traitements. Médecine humaine et pathologie. Université Paris Sud - Paris XI, 2011. Français. ⟨NNT : 2011PA114829⟩. ⟨tel-00722229⟩



Record views


Files downloads